Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	35.84B +78.0%
Revenue (ttm)	7.42B +16.5%
Net Income	920.34M +0.8%
EPS	1.68 +0.0%
Shares Out	543.49M
PE Ratio	39.25
Forward PE	25.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,900
Open	66.15
Previous Close	65.95
Day's Range	64.80 - 67.20
52-Week Range	42.05 - 92.00
Beta	0.52
Analysts	Strong Buy
Price Target	102.98 (+58.92%)
Earnings Date	Jun 2, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,762
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY